![ICON Public Limited Company Website](https://cdn.finchat.io/397809.png)
ICON Public Limited Company
NasdaqGS-ICLR
Company Overview
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Name
ICON Public Limited Company
CEO
Dr. Steven A. Cutler MBA, Ph.D.
Website
www.iconplc.com
Sector
Life Sciences Tools and Services
Year Founded
1990
Profile
Market Cap
$25.51B
EV
$28.62B
Shares Out
82.82M
Revenue
$8,331.89M
Employees
41,100
Margins
Gross
29.74%
EBITDA
20.64%
Operating
13.5%
Pre-Tax
9.05%
Net
8.57%
FCF
14.19%
Returns (5Yr Avg)
ROA
6.57%
ROTA
15.69%
ROE
12.14%
ROCE
13.05%
ROIC
9.94%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
$365.4
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
$506.55M
Net Debt
$3,113.13M
Debt/Equity
0.38
EBIT/Interest
3.78
Growth (CAGR)
Rev 3Yr
37.7%
Rev 5Yr
25.24%
Rev 10Yr
19.43%
Dil EPS 3Yr
7.87%
Dil EPS 5Yr
5.87%
Dil EPS 10Yr
14.63%
Rev Fwd 2Yr
6.53%
EBITDA Fwd 2Yr
9.43%
EPS Fwd 2Yr
15.94%
EPS LT Growth Est
15.41%
Dividends
Yield
—
Payout
—
DPS
—
DPS Growth 3Yr
—
DPS Growth 5Yr
—
DPS Growth 10Yr
—
DPS Growth Fwd 2Yr
—